Silvia S. Martins, PhD
Director of the Substance Use Epidemiology Unit of the Department of Epidemiology, Columbia University Mailman School of Public Health
Director of the Policy and Health Initiatives on Opioids and other Substances interdisciplinary group (PHIOS)
Co-Director of the NIDA T32 Substance Abuse Epidemiology Training Program
Dr. Silvia S. Martins is the Director of the Substance Use Epidemiology Unit of the Department of Epidemiology, Columbia University Mailman School of Public Health and of the Policy and Health Initiatives on Opioids and other Substances interdisciplinary group (PHIOS). She is also the co-director of the NIDA T32 Substance Abuse Epidemiology Training Program in the department and the Course Director of Principles of Epidemiology (P6400).
She has co-authored >200 peer-reviewed epidemiological and substance use articles (>100 first or senior-authored), 80 of them led by her current or former mentees. She has served as PI or MPI of multiple NIH funded grants. Some of her notable research findings have focused on a typology of prescription drug monitoring programs and its impact on prescription opioid and heroin overdoses, machine learning techniques to better understand opioid policies associated with high-opioid prescribing, the effects of recreational cannabis laws in cannabis use outcomes in adolescents and adults in the US, and substance use and psychiatric disorders in child and adolescents in Brazil. She has received several awards for her research and mentoring, including, the 2017 Columbia University Mailman School of Public Health Dean's Award for Excellence in Mentoring. More recently, in 2021, she was selected as one of the School's 2021-2023 Tow Leadership Scholars and she received one of the 2021 Calderone Health Equity awards. Her current research focuses on consequences of medical and recreational marijuana laws in the U.S, recreational marijuana laws in Uruguay, prescription drug monitoring programs, the synergistic effects of opioid policies and marijuana policies on opioid-related harm outcomes, and gambling and impulsive behaviors among minority adolescents in the U.S. She has been continuously funded by NIH since 2006 as a Principal Investigator.